Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[EX Q]: Paragraph: "The story includes the cost of this test $1,625 and mentions that insurance companies currently don’t cover the cost of the new genetic test for breast cancer. The test manufacturer CEO’s speculation that insurance companies will eventually cover the test because it’s easy to perform and ""any doctor can order the test"" is an inappropriate rationale for any screening, especially when such screening may place a woman at risk for unnecessary surgery or other treatments. It is not clear how this test improves on these current practice as there was no evidence presented about it. The story appropriately expresses caution when presenting the value of this new test to predict a woman’s lifetime risk of developing cancer. There is a wide range of experts interviewed, all of whom express concern about the current available evidence for the predictive value of this test. Most experts advise against women taking this test, and the American Cancer Society does not promote the test. The story provides appropriate caveats for women who are considering this test. Namely, a lower than average score might suggest a woman could forgo screening. Women with a higher than average risk score could experience unnecessary anxiety and possibly choose treatments they do not need (such as prophylactic mastectomy). The story does not provide any evidence about the test itself (despite alluding to it). The story does mention that this test has not been validated in an external review, so any evidence would be from company-sponsored studies. Additionally, peer-reviewed studies need to be done to determine the best course of prevention if a woman chooses to take the test and discovers she is at higher risk of developing breast cancer. Because the story raised appropriate questions about the quality of the evidence, we give this a satisfactory score. The story lists the annual incidence of new breast cancers and mortality rate. The story is tempered in reporting about a new genetic test which may or may not be another option for women looking to assess their risk. The story mentions that knowing individual risk may inform a woman’s decision whether to increase surveillance and/or take chemoprevention medication, such as tamoxifen. Several leading breast cancer researchers, a member of the American Cancer Society and a spokesperson for the FDA are interviewed for this story. These interviewees do not have a vested interest in this test–unlike Decode’s chief executive, who is also interviewed, mainly promoting his company’s product. Researchers help educate the reader about a new test may have many more cons than pros. The story does note, via a patient advocate, that some women may still go ahead with the test if they feel it may help guide them in future breast cancer prevention efforts. The story mentions current prevention guidelines for women who are considered at higher than average risk of developing breast cancer. This includes additional surveillance with MRI and mammography, chemoprevention and adopting a healthier lifestyle, namely reducing alcohol consumption and lowering body fat. However, the evidence of survival benefit for lifestyle and screening is fairly limited. Most of recent decrease in breast cancer  mortality is attributed to advances in treatment not necessarily screening. Currently, breast cancer risk for women who do not carry the BRAC1/2 genes is determined via population-based calculators such as the Gail Risk Model. This tool provides an estimated 5-year risk and is only validated for Caucasian women, so a well-validated, individualized predictive test would, in theory, be useful for some women. The test discussed in this story has not been studied long enough, nor have results of company studies been subjected to an external review. The focus of the story is a new, widely available genetic test. The story says that any doctor can order this test to assess a woman’s risk of developing of developing one of the more common forms of breast cancer. The story notes that the FDA does not regulate this or similar types of predictive genetic tests, and there are questions about the validity of tests that have not been subjected to external review. The story notes that there are other genetic tests, but this is one of the first for breast cancer for women who do not carry the BRCA1/2 gene. The story does not mention that there are several other risk calculators to estimate a women’s risk. The story does not rely on the Decode Genetics press release. There is independent reporting and a balanced review of this new genetic test." Claim: Firm says test judges risk for common breast cancers
[EX A]: "The focus of the story is a newly available genetic test to assess a woman’s risk of developing of developing one of the more common forms of breast cancer. The story does not provide any evidence about the test itself (despite alluding to it). The story does mention that this test has not been validated in an external review, so any evidence would be from company-sponsored studies. The story notes that the FDA does not regulate this or similar types of predictive genetic tests, and there is concern about the validity of such tests that have not been subjected to external review. The test manufacturer CEO’s speculation that insurance companies will eventually cover the test because it’s easy to perform and ""any doctor can order the test"" is an inappropriate rationale for any screening, especially when such screening may place a woman at risk for unnecessary surgery or other treatments. The story mentions current prevention guidelines for women who are considered higher than average risk of developing breast cancer. This includes additional surveillance with MRI and mammography, chemoprevention and adopting a healthier lifestyle, namely reducing alcohol consumption and lowering body fat. However,the evidence of survival benefit for lifestyle and screening is fairly limited. Most of recent decrease in breast cancer mortality is attributed to advances in treatment not necessarily screening. Currently, breast cancer risk for women who do not carry the BRAC1/2 genes is determined via population-based calculators such as the Gail Risk Model. This tool provides an estimated 5-year risk and is only validated for Caucasian women, so a well-validated, individualized predictive test would, in theory, be useful for some women. It is not clear how the new genetic test improves on this current practice, as there was no evidence presented. Researchers and clinicians interviewed help educate the reader about a new test may have many more cons than pros. The story does note, via a patient advocate, that some women may still go ahead with the test if they feel it may help guide them in future breast cancer prevention efforts."

[EX Q]: Paragraph: It’s true that eos lip balm users have reported finding black mold inside the product. Reports of black mold found inside eos lip balm have sporadically appeared on social media for years. In February of 2015, one eos lip balm user’s  account of finding black mold inside a container of half-used lip balm gained a lot of attention on Facebook: “I really liked your lip balm, until I got to the middle of mine and found the bottom was full of mold. I thought there was an air bubble in the middle, but it turns out it was a blob of mold. I tried to scrape it off, but it went all the way down to the bottom of the container. Super disappointed and disgusted. That was a waste of my money, and I won’t be buying any of your products again.” In the comments section under the post, many people uploaded  photos of eos lip balm speckled with what they call black mold. And these reports aren’t necessarily new, either. Online reports of black mold found inside of eos lip balm date back to 2012. For its part, eos responded on Facebook that it “very occasionally” gets reports of its lip balm users finding black mold because it’s a  natural product that doesn’t contain any preservatives: “We do very occasionally hear of this. Mold will grow on many surfaces, especially warm and moist places and on products with natural ingredients. The best way to prevent this is to try to not get the lip balm itself wet when applying it (apply to dry lips) and/or let any moisture that’s on the lip balm dry before you put the top back on. I hope this helps and thank you for using our products. “While mold very rarely grows on our lip balm, it has been known to happen, especially with all-natural ingredients. Our policy is that we’re happy to replace any defective lip balm so long as the customer provides a picture. So if you want to send a picture of the moldy lip balm to  [email protected], we’d be happy to send a coupon for a replacement. Thanks again for the feedback as it helps us improve.” The USDA  reports that most molds found on food and consumer products are not toxic, but it is possible for some varieties to cause allergic reactions or respiratory problems. Comments Claim:   Black mold has been found inside eos lip balm containers. 
[EX A]: Customers Find Black Mold Inside Eos Lip Balm.  

[EX Q]: Paragraph: The flight contained 2.5 million surgical masks, 10 million gloves as well as goggles and thermometers worth more than 3 million Swiss francs ($3.1 million), and made by Sinopharm Group Co Ltd.  Another delivery arrived in Zurich on Sunday evening on a chartered Swiss airline flight from Shanghai carrying protective gowns for dozens of health care facilities. Further flights with additional equipment are planned. Christophe Weber, president of the Swiss-Chinese Chamber of Commerce for western Switzerland, who helped organise the Geneva delivery, said that the order was placed in response to appeals from doctors and pharmacists amid serious supply shortages. “I always considered that we, Switzerland, had the quotas necessary for protective medical equipment and it was unfortunately not the case and it became urgent to take action,” he said at Geneva’s Cointrin airport. About a dozen police surrounded the cargo. The equipment was inspected inside an airport warehouse and will be moved to another secret location for redistribution, with police escorts, later on Monday. Weber said the government knew about the delivery and had approved of it. “The competition is extremely lively with the Americans now joining in the bidding and we know about their firepower,” said Vincent Subilia, director general of the Geneva Chamber of Commerce, who was also involved with the shipment, referring to masks as “blue gold”. A German official last week said that an order of 200,000 masks bound for Germany had been “confiscated” in Bangkok and diverted to the United States, calling it an “act of modern piracy”. The United States had no knowledge of the shipment, a spokesman said. Switzerland reported 21,652 positive COVID-19 cases on Monday and 584 deaths, with the rate of new confirmed increases slowing. It has mobilised the army to help back up hospitals. Medical aid organisation Medecins Sans Frontieres is helping in the University Hospital of Geneva, which is one of the facilities due to receive equipment. It was not immediately clear if the additional supplies would fill the gap in Switzerland’s supplies. Daniel Koch, the federal government’s point man for battling the epidemic, said on Swiss television RTS on Sunday: “There are stocks for hospitals, for professionals, for retirement homes, and the distribution system is working.”  ($1 = 0.9790 Swiss francs) Claim: Chinese masks, or 'blue gold', arrive for Swiss hospitals.
[EX A]:
A Boeing 747 landed in Geneva on Monday with 92 tonnes of protective medical equipment including masks made in China for distribution to 13 Swiss hospitals and pharmaceutical associations as they battle the COVID-19 pandemic.